13G Filing: JPMorgan Chase & Co and Kite Pharma Inc. (KITE)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
JPMORGAN CHASE CO 13-6 1,184,466 0 1,214,765 0 1,215,790 2.1%

Page 1 of 3 – SEC Filing



UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934

(Amendment No.
01)*
KITE PHARMA, INC. 

(Name
of Issuer)
Common Stock, par value $0.001 per share

(Title of Class of Securities)

49803L109

(CUSIP Number)

September 29, 2017

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x
Rule
13d-1(b)

o
Rule
13d-1(c)

o
Rule
13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to
be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


Follow Kite Pharma Inc. (NASDAQ:KITE)

Page 2 of 3 – SEC Filing

CUSIP
No. 
49803L109    
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
JPMORGAN CHASE & CO
13-62624428
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
INSTRUCTIONS)

(a)
o
(b)
o
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES
BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:
5 SOLE VOTING POWER
1,184,466
6 SHARED VOTING POWER
0
7 SOLE DISPOSITIVE POWER
1,214,765
8 SHARED DISPOSITIVE POWER
0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,215,790
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS)
o
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.1%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC

FOOTNOTES

Follow Kite Pharma Inc. (NASDAQ:KITE)

Page 3 of 3 – SEC Filing

SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and correct.
  JPMorgan Chase & Co
 
       

Date:
October 05, 2017
By:
/s/
Michael T. Lees
 
   
Name: Michael T. Lees
 
   
Title:
Executive Director
 
       
Footnotes:
Attention:
Intentional
misstatements or omissions of fact constitute Federal criminal violations (See
18 U.S.C. 1001)
 

Follow Kite Pharma Inc. (NASDAQ:KITE)